* Recommended for adults with compromised immune systems
* Prevnar 13 seen as one of Pfizer's most important products
* Shares fall 5 cents
June 20 An advisory committee for the U.S.
Centers for Disease Control and Prevention voted on Wednesday to
recommended expanded use of Pfizer Inc's Prevnar 13
vaccine to include adults 19 and older with compromised immune
systems due to conditions such as HIV infection, cancer and
advanced kidney disease.
The Advisory Committee on Immunization Practices
(ACIP)favored the expanded use by a vote of 14-0 with one
abstention, the CDC said.
Prevnar 13, one of Pfizer's most important products,
prevents pneumococcal pneumonia or invasive disease. Wall Street
analysts, on average, have forecast Prevnar 13 sales will reach
$6.75 billion by 2016. The company reported sales of $941
million in the first quarter.
"While we view this (recommendation) as an incremental
positive, we think the Street expected a positive outcome," ISI
Group analyst Mark Schoenebaum said in a research note.
Pfizer shares were off 9 cents at $22.62 in midday trading
on the New York Stock Exchange.
Prevnar 13 was initially approved by the U.S. Food and Drug
Administration in 2010 for the prevention of invasive
pneumococcal disease caused by the 13 serotypes included in the
vaccine in infants and children from 6 weeks through 5 years
The FDA in December approved Prevnar 13 for adults age 50
and older. ACIP has not yet recommended the vaccine for that
"We are committed to continuing discussions with the ACIP
with the aim of expanding the recommendations to include all
adults 50 years of age and older - a population rapidly
increasing in the United States and at risk for developing
vaccine-type pneumococcal pneumonia and invasive disease,"
Pfizer said in a statement.
Pfizer is expecting data next year from a Prevnar 13 trial
of more than 84,000 subjects 65 and older to determine if the
vaccine is effective in preventing the first episode of
community-acquired pneumonia caused by the 13 pneumococcal
serotypes in the vaccine.
ACIP is likely awaiting results from that trial, called
CAPITA, before making a recommendation for the vaccine's use in
"The key event for Prevnar 13 remains the data readout in
2013 from the CAPITA adult outcomes study," Schoenebaum said.
The vaccine is not approved for those between the ages of 6